Clinicopathologic features and prognostic factors in alpha‐fetoprotein‐producing gastric cancers: Analysis of 104 cases

Liu, Xiaowen; Cheng, Ya-Min; Sheng, Weiqi; Lu, Haizhou; Xu, Yu; Long, Ziwen; Zhu, Huiyan; Wang, Yanong

doi:10.1002/jso.21624

Cited by 145 publications

(158 citation statements)

References 30 publications

Supporting

Mentioning

146

Contrasting

Order By: Relevance

“…Four discussion points were evaluated for CEA, CA19-9, and CA72-4 from selected articles as follows: (1) positive rates, (2) clinicopathological significance, (3) prognostic impact, and (4) clinical impact during follow-up after surgery and/or during chemotherapy. Finally, we selected 10 other publications that focused only on AFP [51][52][53][54], CA125 [3,[55][56][57], and STN [58,59] (Fig. 1).…”

Section: Manuscript Selectionmentioning

confidence: 99%

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

et al. 2013

View full text Add to dashboard Cite

The aim of this review was to evaluate the clinical significance of serum tumor markers, particularly CEA, CA19-9, and CA72-4, in patients with gastric cancer. A systematic literature search was performed using PubMed/MEDLINE with the keywords ''gastric cancer'' and ''tumor marker,'' to select 4,925 relevant reports published before the end of November 2012. A total of 187 publications contained data for CEA and CA19-9, and 19 publications contained data related to all three tumor markers. The positive rates were 21.1 % for CEA, 27.8 % for CA19-9, and 30.0 % for CA72-4. These three markers were significantly associated with tumor stage and patient survival. Serum markers are not useful for early cancer, but they are useful for detecting recurrence and distant metastasis, predicting patient survival, and monitoring after surgery.

show abstract

Section: Manuscript Selectionmentioning

confidence: 99%

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

et al. 2013

View full text Add to dashboard Cite

show abstract

“…12 Various reports have shown that AFP producing carcinoma of the stomach has a more aggressive behavior than the common gastric cancers in the form of higher incidence of vascular invasion, lymph node and liver metastasis. 13 Data regarding optimum therapy of AFPGC is sparse. The treatment is similar to that of common gastric adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…10 They have high metastatic potential and possibility of vascular invasion, liver and lymph nodal metastases resulting in poor prognosis. 2 In situations where associated liver mass is seen, it may be mistaken for coexistent hepatocellular carcinoma, like the index case.…”

mentioning

confidence: 99%

Alpha-fetoprotein producing Gastric carcinoma : A rare entity

Yadav¹

2016

View full text Add to dashboard Cite

“…AFP-GC may be divided into two subtypes, consisting of AFP-producing non-hepatoid adenocarcinoma and hepatoid adenocarcinoma. AFP-GC is usually diagnosed in the advanced stages of disease and demonstrates a poor prognosis (20)(21)(22). In patients exhibiting serum AFP levels of >300 ng/ml, the 1-, 3-, and 5-year survival rates are 15.4, 7.7%, and 0%, respectively.…”

Section: Introductionmentioning

confidence: 99%

α-fetoprotein-producing gastric carcinoma: A case report of a rare subtype and literature review

Sun

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. α-fetoprotein (AFP)-producing gastric carcinoma is a rare type of gastric cancer, and the characteristics have not yet been fully elucidated. The present study reports the case of a patient with this type of gastric cancer. A 66-year-old male was referred to the Department of Gastrointestinal Surgery, Qianfoshan Hospital, Shandong University (Jinan, China) with a 20-day history of retrosternal pain. A computed tomography (CT) scan revealed a thickening of the wall of the cardia and massive lymph node swelling in the region of the lesser curvature of the stomach. A laboratory investigation revealed that the serum AFP levels of the patient were elevated to 46.49 ng/ml (normal level, <12.00 ng/ml), and the serum carcinoembryonic antigen (CEA) levels were 382.22 ng/ml (normal range, <5.00 ng/ml). An endoscopy revealed an elevated tumor and AFP-producing gastric cancer was diagnosed. As the tumor was surgically unresectable, the patient received systemic adjuvant chemotherapy [consisting of 1 cycle of oxaliplatin (150 mg; day 1)-fluorouracil(1.0 g; days 2-6)-calcium folinate (0.3 g; days 2-6), 4 cycles of paclitaxel (80 mg; day 1 and 8, repeated day 21) and capecitabine (1,000 g/m 2 , twice daily; days 1-14, repeated day 21), and 2 cycles of oxaliplatin (130 mg/m 2 ; day 1, repeated day 21) and S-1 (100 mg/d; day 1-day 14; repeated day 21)]. During the chemotherapy intermission, the patient experienced partial remission; the serum AFP levels remained between 44.5 and 32.7 ng/ml, and serum CEA levels decreased to a normal level. The CT scan revealed that the enlarged lymph nodes of the patient had decreased in size. During the preoperative examinations, an abdominal CT scan revealed no metastasis to the liver. A radical gastrectomy was performed on October 20, 2014. Additionally, the tumor did not demonstrate the diffusion of AFP. The histopathological examination revealed a poorly differentiated adenocarcinoma, with local and neuroendocrine differentiation and no hepatoid features. According to these histopathological findings, the tumor was diagnosed as AFP-producing non-hepatoid adenocarcinoma of the stomach. The patient was treated with systemic immunity-enhancing therapy and has been free of recurrence for 2 months. The present study describes a rare case of AFP-producing non-hepatoid adenocarcinoma of the stomach, with a review of the literature and an investigation of the clinical features. Introductionα-fetoprotein (AFP) is an oncofetal glycoprotein that is mainly produced by the yolk sac and liver during fetal development, and to a lesser extent, in the fetal gastrointestinal tract (1,2). The greatest serum AFP levels are observed between 12-15 weeks after birth, which decrease to normal adult levels subsequent to approximately one year (3,4). AFP is detected in the serum of adults with hepatocellular carcinoma, yolk sac tumors and noncancerous liver disease (2-6). Rising AFP levels may also be detected in the malignant tumors of various organs, including the stomach, lung, pancreas, colon, bladder ...

show abstract

Clinicopathologic features and prognostic factors in alpha‐fetoprotein‐producing gastric cancers: Analysis of 104 cases

Abstract: AFP-positive gastric cancer had more aggressive behavior than that of AFP-negative gastric cancer. In addition to surgery, multimodal therapy should be considered.

Cited by 145 publications

References 30 publications

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

Alpha-fetoprotein producing Gastric carcinoma : A rare entity

α-fetoprotein-producing gastric carcinoma: A case report of a rare subtype and literature review

Contact Info

Product

Resources

About